Form 4: Rocket Pharmaceuticals Director Receives Significant RSU Grant

Pedro P. Granadillo, a Director at Rocket Pharmaceuticals, Inc., was granted 54,734 restricted stock units, including units in lieu of director fees, vesting in June 2026.

Summary

• Pedro P. Granadillo, a Director of Rocket Pharmaceuticals, Inc. (RCKT), received a grant of 54,734 restricted stock units (RSUs) on June 18, 2025.
• Of the total, 30,000 RSUs were a general grant.
• An additional 24,734 RSUs were issued in lieu of $70,000 in director retainer fees.
• All 54,734 RSUs convert to common stock on a one-for-one basis and are scheduled to vest in full on June 18, 2026.
• Following these transactions, Pedro P. Granadillo beneficially owns 54,734 shares directly.

Sentiment

Score: 7

Explanation: The grant of RSUs to a director is generally positive as it aligns interests and conserves cash, indicating stability in compensation structure.

Positives

• The grant of restricted stock units aligns the director's interests with long-term shareholder value.
• Issuance of RSUs in lieu of cash fees conserves company cash.

Risks

• The value of the RSUs is subject to the future performance of Rocket Pharmaceuticals' common stock.
• The RSUs will not vest if the director's service terminates before June 18, 2026, under typical RSU agreements.

Future Outlook

The RSUs are set to vest on June 18, 2026, indicating a future milestone for the director's equity compensation.

Industry Context

Equity grants, particularly RSUs, are a common form of executive and director compensation in the biotechnology and pharmaceutical industries, aligning long-term incentives with company performance.

Comparison to Industry Standards

• Granting RSUs as part of director compensation is a standard practice across many industries, including biotech, to align director interests with shareholder value.
• The specific number of units (54,734) and the conversion of $70,000 in fees to RSUs would need comparison with similar-sized biotech companies' director compensation packages to assess if it's above, below, or in line with industry benchmarks. Without specific comparable data, a detailed assessment is not possible from this document alone.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of RSUs aligns the director's interests with shareholders, potentially encouraging long-term value creation. The issuance of RSUs in lieu of cash fees also reduces immediate cash outflow.

Next Steps

• The RSUs are expected to vest on June 18, 2026.

Key Dates

Keywords

Rocket Pharmaceuticals, RCKT, Form 4, Insider Transaction, Restricted Stock Units, RSUs, Director Compensation, Equity Grant, Beneficial Ownership